"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic. Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.Beyond disgusting," said Sen. Bernie Sanders.